Amy Emerson is the Chief Executive Officer at the MAPS Public Benefit Corporation (MAPS PBC), a fully owned subsidiary of the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS).
Working for almost two decades to make MDMA a legal, FDA-approved medicine, Amy began as a pro bono consultant for MAPS in 2003, helping to create MAPS’ clinical department and managing the MDMA Clinical Development Program.
Her painstaking time and efforts have played a key role in seeing MDMA-assisted psychotherapy as a treatment for post-traumatic stress disorder (PTSD) through clinical trials, driving it ever-closer to being a legal, accessible therapeutic treatment in the US and abroad.
Read moreMAPS Founder and Executive Director Rick Doblin, Ph.D., sits down with Aubrey Marcus to explain MAPS' multiple research, policy, and education priorities in the context of our larger, long-term goal of mass mental health.
"I hope in the big picture, by 2050, we'll have enough people with an understanding of how to use psychedelics for personal, emotional, and spiritual growth that we'll have a more spiritualized humanity to turn us more towards saving the planet from mass weapons, climate change, and prejudice," explains Doblin.
Read moreCould psychedelics ease mental health toll from COVID-19, and other crises?
Read moreBBC Future profiles MAPS Founder Rick Doblin, Ph.D., in an extensive article exploring the international impact of psychedelics on science, drug policy, culture, and medicine.
By highlighting the rapid increase in psychedelic research over the past ten years, Ed Prideaux of BBC explains how clinical trial results, favorable media coverage, and the potential development of new mental health treatments are steadily moving the public perception of psychedelics toward mainstream acceptance.
"Now the efforts of Doblin and others are finally paying off,” writes Prideaux. "Promising clinical trials suggest that psychedelics may prove game-changing treatments for depression, PTSD and addiction."
Read morePsychedelic use on the rise as Gen Z seeks to ‘enhance connectedness’.
The latest data shows the highest rates of psychedelic use among college students since 1982.
Read more‘The End In Mind’ conference answers questions about psychedelics for end-of-life patients.
Read moreThe growing legitimacy of psychedelics as therapies promises to transform how we view the extraordinary.
Read moreWhat does ketamine do to your brain?
Much of how ketamine works is a mystery, but the picture is slowly coming into focus.
Read morePsychedelic treatments are here, but doctors aren’t prepared.
So says Rick Doblin, founder and executive director of the Multidisciplinary Assn. for Psychedelic Studies.
Read more
Quisque iaculis facilisis lacinia. Mauris euismod pellentesque tellus sit amet mollis.